EMEA Point-of-care Diagnostics Market

EMEA Point-of-care Diagnostics Market by Products (Glucose Testing [Over the Counter and Prescribed], Cardiac Markers, Fertility, Blood Gas & Electrolytes, Decentralized Clinical Chemistry, Infectious Disease Testing, Coagulation [Over the Counter and Prescribed], Primary Care Systems, Hematology, Urinalysis, Drug Abuse Testing, and Others), End-users (Hospitals, Clinics, Laboratories, Assisted Living Healthcare Facilities, Home Healthcare Facilities, and Others), and Regions (Europe, Middle East and Africa)- Europe, Middle East and Africa Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1884
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 214
  • Format:
  • Pub. Date: Upcoming
  • Share:

The Europe and Middle East & Africa (EMEA) point-of-care diagnostics market size is expected to expand at a substantial CAGR during the forecast period, 2021-2028. The growth of the market is attributed to the increasing number of global population along with high prevalence rates of recurring diseases.

EMEA Point-of-care Diagnostics Market

The point-of-care diagnostics include the identification of various abstracts related to applied trials, observations, and simulations for the treatment required. This test evaluation report and a summary of the study is usually forwarded to the concerned clinics, which take the major decision to proper treatment for the disease of patients. Over the years, various kinds of point-of-care-tests were developed to study different anatomies of the body, be it internal or external. For instance, after the introduction of urine test strips, in which the patient’s urine strip is examined on a separate apparatus for the detection of drugs or toxic, the test result of portable ultrasonography is found better improvement and showing accurate readings in limited time.

The idea behind the launch of point-of-care tests was to conduct tests immediately, which are convenient to the patients. Using this diagnostic data, it is likely that the physician and the healthcare team can work efficiently in deciding the treatment for patients. According to the WHO survey statistics in 2020, the point-of-care testing devices are adopted by one-in-five patients, which is expected to increase to one-in-three by 2025. The COVID-19 pandemic has accelerated the growth of the market globally, particularly the EMEA primary care point-of-care diagnostics market. Point-of-care testing is increasingly adopted in various hospitals as it is considered to be one of the perfect tools and analysis for this pandemic situation. A large amount of funding invested by hospital bodies to start research of the point-of-care-tests, fueling the growth of the EMEA point-of-care diagnostics market.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing the range of applications of the point-of-care diagnostics testing along with the decentralization of healthcare facilities for providing remote access are projected to boost the market growth during the forecast period.
  • Rapid advancement of point-of-care testing devices and ease of use as well as portability are major factors driving the market expansion in the coming years.
  • Requirement of special environment to store devices and equipment used in point-of-care testing leads to high maintenance cost, thereby, acting as a key factor hindering the point-of-care diagnostics market growth in the EMEA region.
  • Lack of reliability in the results obtained by the point-of-care testing devices present as a major factor to restrict the market growth. The tests conducted by these devices are meant for preliminary reports alone and not for final analysis.
  • R&D investment and technological advancement are expected to offer significant opportunities for the market players. Researchers and scientists have now discovered innovative technology such as the Picture Archiving and Communication Systems or the PACS and the Electronic Medical Records or the EMR as IT support systems.        

Scope of the Report

The report on the EMEA point-of-care diagnostics market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

EMEA Point-of-care Diagnostic Market - EMEA Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Glucose Testing [Over the Counter and Prescribed], Cardiac Markers, Fertility, Blood Gas & Electrolytes, Decentralized Clinical Chemistry, Infectious Disease Testing, Coagulation [Over the Counter and Prescribed], Primary Care Systems, Hematology, Urinalysis, Drug Abuse Testing, and Others), and End-users (Hospitals, Clinics, Laboratories, Assisted Living Healthcare Facilities, Home Healthcare Facilities, and Others)

Regional Scope

Europe and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast

Key Players Covered in the Report

Beckman Coulter Inc; Roche Diagnostics; Siemens Healthcare; Abbott Laboratories; Danaher Corporation; Becton, Dickinson and Company; bioMerieux SA; Abaxis Inc; Alere Inc; Qiagen NV; Spectral Diagnostic Inc; HemoCue AB; Nova Biomedical; and Quidel Corporation

EMEA Point-of-care Diagnostics Market Segment Insights

Glucose testing segment is projected to represent a large market share

Based on the products, the EMEA point-of-care diagnostics market is segmented into glucose testing, cardiac markers, fertility, blood gas & electrolytes, decentralized clinical chemistry, infectious disease testing, coagulation, primary care systems, hematology, urinalysis, drug abuse testing, and others. Glucose testing and coagulation are further bifurcated into the over the counter or the OTC and the prescribed. The glucose testing segment is expected to constitute a major share of the market during the forecast period, 2021-2028 owing to the increasing adoption of various self-testing glucose devices. They play an essential role in terms of regulating glycemic levels on a regular basis. This is also now anticipated for providing positive health outcomes including diabetes. Meanwhile, the cardiac markers segment is anticipated to exhibit a robust growth with a CAGR of more than 8.1% during the forecast period. This segment growth can be attributed to the escalating number of cardiac diseases because of the sedentary lifestyle of people, along with the advancement of cardiac markers equipment with boosted accuracy and high precision.

EMEA Point-of-care Diagnostics Market

Clinics is expecting to grow at a significant pace

On the basis of end-users, the EMEA point-of-care diagnostics market is divided into hospitals, clinics, laboratories, assisted living healthcare facilities, home healthcare facilities, and others. The clinics segment is expected to constitute a major market share accounting for more than 38% of the total market revenue during the forecast period. The segment growth can be attributed to the high volumes of procedures related with the establishments of point-of-care diagnostics devices along with the increase in rapid clinics using only specific point-of-care diagnostic tests. On the other hand, the home healthcare facilities segment is expected to register a substantial CAGR during the forecast years owing to the increasing need of home healthcare setting for various diseases treatment. Moreover, the rising demand for continuous monitoring for the treatment of diseases and rising awareness of the patients, especially in the EMEA region present key drivers for the segment growth.

EMEA Point-of-care Diagnostics Market

Europe is anticipated to dominate the market

On the basis of regions, the EMEA point-of-care diagnostics market is bifurcated into Europe and Middle East & Africa. Europe is expecting to expand at an impressive CAGR during the forecast period, 2021-2028 owing to the introduction of various government contracts on the healthcare infrastructure development that are contributing towards the rising demand for the point-of-care diagnostics equipment. On the other hand, the market in Middle East & Africa is projected to hold a key market share in the coming years. In the regions, countries such as Saudi Arabia and the United Arab Emirates are expected to register robust CAGR during the forecast period due to the levy of easy market access. The breakout of the COVID-19 pandemic is also a major factor for this given regional growth.

Segments

Segments Covered in the Report

The EMEA point-of-care diagnostics market size has been segmented in terms of

Products

  • Glucose Testing
    • Over the Counter
    • Prescribed
  • Cardiac Markers
  • Fertility
  • Blood Gas & Electrolytes
  • Decentralized Clinical Chemistry
  • Infectious Disease Testing
  • Coagulation
    • Over the Counter
    • Prescribed
  • Primary Care Systems
  • Hematology
  • Urinalysis
  • Drug Abuse Testing
  • Others

End-users

  • Hospitals
  • Clinics
  • Laboratories
  • Assisted Living Healthcare Facilities
  • Home Healthcare Facilities
  • Others

Regions

  • Europe
  • Middle East & Africa

Key Players

  • Beckman Coulter Inc.
  • Roche Diagnostics
  • Siemens Healthcare
  • Abbott Laboratories
  • Danaher Corporation
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Abaxis Inc
  • Alere Inc
  • Qiagen NV
  • Spectral Diagnostic Inc
  • HemoCue AB
  • Nova Biomedical
  • Quidel Corporation

Competitive Landscape

Major players competing in the global pharmacogenomics technology market are Beckman Coulter Inc; Roche Diagnostics; Siemens Healthcare; Abbott Laboratories; Danaher Corporation; Becton, Dickinson and Company; bioMerieux SA; Abaxis Inc; Alere Inc; Qiagen NV; Spectral Diagnostic Inc; HemoCue AB; Nova Biomedical; and Quidel Corporation.

These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, Roche Diagnostics bought 12% of the IQuum stake back in 2014 and now acquired the entire company in 2019.  The development was aimed to strengthen the company’s point-of-care diagnostics segment in the molecular diagnostics.


Players are simultaneously looking to produce innovative products in order to get a competitive edge in the market. For instance, Roche Diagnostics launched the CoaguChek Pro IV point-of-care system, which could immediately diagnose the presence of the COVID-19 in the testing and check the coagulation level of the patient’s blood for reporting analysis.

EMEA Point-of-care Diagnostics Market

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Point-of-care Diagnostics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Point-of-care Diagnostics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Point-of-care Diagnostics Market - Supply Chain
  4.5. Global Point-of-care Diagnostics Market Forecast
     4.5.1. Point-of-care Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Point-of-care Diagnostics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Point-of-care Diagnostics Market Absolute $ Opportunity
5. Global Point-of-care Diagnostics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Point-of-care Diagnostics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Point-of-care Diagnostics Demand Share Forecast, 2019-2026
6. North America Point-of-care Diagnostics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Point-of-care Diagnostics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Point-of-care Diagnostics Demand Share Forecast, 2019-2026
7. Latin America Point-of-care Diagnostics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Point-of-care Diagnostics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Point-of-care Diagnostics Demand Share Forecast, 2019-2026
8. Europe Point-of-care Diagnostics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Point-of-care Diagnostics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Point-of-care Diagnostics Demand Share Forecast, 2019-2026
9. Asia Pacific Point-of-care Diagnostics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Point-of-care Diagnostics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Point-of-care Diagnostics Demand Share Forecast, 2019-2026
10. Middle East & Africa Point-of-care Diagnostics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Point-of-care Diagnostics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Point-of-care Diagnostics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Point-of-care Diagnostics Market: Market Share Analysis
  11.2. Point-of-care Diagnostics Distributors and Customers
  11.3. Point-of-care Diagnostics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Beckman Coulter Inc. Roche Diagnostics Siemens Healthcare Abbott Laboratories Danaher Corporation

Segments Covered in the Report

The EMEA point-of-care diagnostics market size has been segmented in terms of

Products

  • Glucose Testing
    • Over the Counter
    • Prescribed
  • Cardiac Markers
  • Fertility
  • Blood Gas & Electrolytes
  • Decentralized Clinical Chemistry
  • Infectious Disease Testing
  • Coagulation
    • Over the Counter
    • Prescribed
  • Primary Care Systems
  • Hematology
  • Urinalysis
  • Drug Abuse Testing
  • Others

End-users

  • Hospitals
  • Clinics
  • Laboratories
  • Assisted Living Healthcare Facilities
  • Home Healthcare Facilities
  • Others

Regions

  • Europe
  • Middle East & Africa

Key Players

  • Beckman Coulter Inc.
  • Roche Diagnostics
  • Siemens Healthcare
  • Abbott Laboratories
  • Danaher Corporation
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Abaxis Inc
  • Alere Inc
  • Qiagen NV
  • Spectral Diagnostic Inc
  • HemoCue AB
  • Nova Biomedical
  • Quidel Corporation

Major players competing in the global pharmacogenomics technology market are Beckman Coulter Inc; Roche Diagnostics; Siemens Healthcare; Abbott Laboratories; Danaher Corporation; Becton, Dickinson and Company; bioMerieux SA; Abaxis Inc; Alere Inc; Qiagen NV; Spectral Diagnostic Inc; HemoCue AB; Nova Biomedical; and Quidel Corporation.

These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, Roche Diagnostics bought 12% of the IQuum stake back in 2014 and now acquired the entire company in 2019.  The development was aimed to strengthen the company’s point-of-care diagnostics segment in the molecular diagnostics.


Players are simultaneously looking to produce innovative products in order to get a competitive edge in the market. For instance, Roche Diagnostics launched the CoaguChek Pro IV point-of-care system, which could immediately diagnose the presence of the COVID-19 in the testing and check the coagulation level of the patient’s blood for reporting analysis.

EMEA Point-of-care Diagnostics Market

Buy Report